Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion Pharmaceuticals is harnesing the power of artificial intelligence to rapidly develop new drugs. The drugmaker's former lead candidate failed to show evidence of efficacy in a phase 2 study ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Samsungに所属するAI研究者のAlexia Jolicoeur-Martineau氏が小型かつ高性能なAIモデル「Tiny Recursion Model(TRM)」を開発しました。TRMは再帰的推論と呼ばれる手法を採用しており、わずか700万パラメーターという小型モデルでありながらGemini 2.5 Proを超えるベンチマーク ...